Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.41
At close: May 13, 7:52 AM EDT
$1.27
-0.14-9.93%
Pre-Market: May 13, 7:52 AM EDT
Comments
Loading...
HOOKIPA Pharma Analyst Ratings and Price Targets | NASDAQ:HOOK | Benzinga
HOOKIPA Pharma Inc has a consensus price target of $5.96 based on the ratings of 8 analysts. The high is $23 issued by JMP Securities on July 26, 2024. The low is $0.5 issued by B of A Securities on December 2, 2022. The 3 most-recent analyst ratings were released by RBC Capital, JMP Securities, and RBC Capital on December 20, 2024, November 21, 2024, and November 15, 2024, respectively. With an average price target of $19 between RBC Capital, JMP Securities, and RBC Capital, there's an implied 1396.06% upside for HOOKIPA Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
JMP Securities
JMP Securities
Truist Securities
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for HOOKIPA Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/10/2025 | Buy Now | — | HC Wainwright & Co. | Arthur He34% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/20/2024 | Buy Now | 57.48% | RBC Capital | Brian Abrahams49% | $48 → $2 | Downgrade | Outperform → Sector Perform | Get Alert |
| 11/21/2024 | Buy Now | 451.18% | JMP Securities | Roy Buchanan35% | $24 → $7 | Maintains | Market Outperform | Get Alert |
| 11/15/2024 | Buy Now | 3679.53% | RBC Capital | Brian Abrahams49% | $50 → $48 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | 1789.76% | JMP Securities | Roy Buchanan35% | $23 → $24 | Maintains | Market Outperform | Get Alert |
| 07/26/2024 | Buy Now | 1711.02% | JMP Securities | Jason Butler50% | $50 → $23 | Maintains | Market Outperform | Get Alert |
| 06/05/2024 | Buy Now | 372.44% | HC Wainwright & Co. | Arthur He34% | $5 → $6 | Maintains | Buy | Get Alert |
| 05/21/2024 | Buy Now | 293.7% | RBC Capital | Brian Abrahams49% | $5 → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 04/26/2024 | Buy Now | 293.7% | HC Wainwright & Co. | Arthur He34% | $6.5 → $5 | Maintains | Buy | Get Alert |
| 03/25/2024 | Buy Now | 293.7% | RBC Capital | Brian Abrahams49% | $5 → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 03/25/2024 | Buy Now | 411.81% | HC Wainwright & Co. | Arthur He34% | $6.5 → $6.5 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2024 | Buy Now | 293.7% | RBC Capital | Brian Abrahams49% | $6 → $5 | Maintains | Outperform | Get Alert |
| 09/27/2023 | Buy Now | 451.18% | RBC Capital | Brian Abrahams49% | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 09/06/2023 | Buy Now | 214.96% | Truist Securities | Asthika Goonewardene41% | → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 411.81% | HC Wainwright & Co. | Arthur He34% | $8 → $6.5 | Maintains | Buy | Get Alert |
| 06/30/2023 | Buy Now | 451.18% | RBC Capital | Brian Abrahams49% | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 06/05/2023 | Buy Now | 77.17% | Morgan Stanley | Vikram Purohit38% | $2 → $2.25 | Maintains | Equal-Weight | Get Alert |
| 05/12/2023 | Buy Now | 529.92% | HC Wainwright & Co. | Arthur He34% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2023 | Buy Now | 214.96% | Truist Securities | Asthika Goonewardene41% | $11 → $4 | Maintains | Buy | Get Alert |
| 03/16/2023 | Buy Now | 529.92% | HC Wainwright & Co. | Arthur He34% | → $8 | Reiterates | → Buy | Get Alert |
| 12/02/2022 | Buy Now | -60.63% | B of A Securities | Alec Stranahan33% | $6 → $0.5 | Downgrade | Buy → Underperform | Get Alert |
| 11/15/2022 | Buy Now | 451.18% | RBC Capital | Brian Abrahams49% | $8 → $7 | Maintains | Outperform | Get Alert |
| 08/23/2022 | Buy Now | 766.14% | Truist Securities | Asthika Goonewardene41% | $16 → $11 | Maintains | Buy | Get Alert |
| 08/11/2022 | Buy Now | 136.22% | SVB Leerink | Andrew Berens48% | $4 → $3 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for HOOKIPA Pharma (HOOK) stock?
The latest price target for HOOKIPA Pharma (NASDAQ:HOOK) was reported by HC Wainwright & Co. on January 10, 2025. The analyst firm set a price target for $0.00 expecting HOOK to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for HOOKIPA Pharma (HOOK)?
The latest analyst rating for HOOKIPA Pharma (NASDAQ:HOOK) was provided by HC Wainwright & Co., and HOOKIPA Pharma downgraded their neutral rating.
When was the last upgrade for HOOKIPA Pharma (HOOK)?
There is no last upgrade for HOOKIPA Pharma
When was the last downgrade for HOOKIPA Pharma (HOOK)?
The last downgrade for HOOKIPA Pharma Inc happened on January 10, 2025 when HC Wainwright & Co. changed their price target from N/A to N/A for HOOKIPA Pharma Inc.
When is the next analyst rating going to be posted or updated for HOOKIPA Pharma (HOOK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HOOKIPA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HOOKIPA Pharma was filed on January 10, 2025 so you should expect the next rating to be made available sometime around January 10, 2026.
Is the Analyst Rating HOOKIPA Pharma (HOOK) correct?
While ratings are subjective and will change, the latest HOOKIPA Pharma (HOOK) rating was a downgraded with a price target of $0.00 to $0.00. The current price HOOKIPA Pharma (HOOK) is trading at is $1.27, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
